Updates in adjuvant systemic therapy for melanoma.

Journal Article (Journal Article;Review)

There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.

Full Text

Duke Authors

Cited Authors

  • Kwak, M; Farrow, NE; Salama, AKS; Mosca, PJ; Hanks, BA; Slingluff, CL; Beasley, GM

Published Date

  • January 2019

Published In

Volume / Issue

  • 119 / 2

Start / End Page

  • 222 - 231

PubMed ID

  • 30481375

Pubmed Central ID

  • PMC6330126

Electronic International Standard Serial Number (EISSN)

  • 1096-9098

Digital Object Identifier (DOI)

  • 10.1002/jso.25298


  • eng

Conference Location

  • United States